ELDN ▲ +0.4% - Eledon Pharmaceuticals, Inc.
$ELDN - Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual Meeting
26-OCT-2026 07:00 AM ET
Share this post
More filings for $ELDN
ELDN ▲ +4.1% - Eledon Pharmaceuticals, Inc.Sep 22, 2026ELDN ▲ +1.7% - Eledon Pharmaceuticals, Inc.Sep 9, 2026ELDN ▲ +0.7% - Eledon Pharmaceuticals, Inc.Sep 3, 2026$ELDN SEC Filing Update (31-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 31, 2026
View full $ELDN filing history →💬 Comments
Loading comments…
Leave a comment